Nuveen’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.26B Sell
2,019,974
-45,090
-2% -$30.7M 0.3% 61
2026
Q1
$1.6B Buy
2,065,064
+54,547
+3% +$41.8M 0.43% 39
2025
Q4
$1.55B Buy
2,010,517
+835,240
+71% +$567M 0.41% 38
2025
Q3
$661M Buy
1,175,277
+333,728
+40% +$189M 0.17% 101
2025
Q2
$442M Buy
841,549
+299,531
+55% +$167M 0.12% 146
2025
Q1
$344M Buy
542,018
+66,388
+14% +$45.7M 0.1% 176
2024
Q4
$339M Sell
475,630
-211,009
-31% -$177M 0.1% 180
2024
Q3
$722M Buy
686,639
+84,314
+14% +$93.8M 0.2% 93
2024
Q2
$633M Buy
602,325
+63,575
+12% +$61.6M 0.19% 100
2024
Q1
$519M Buy
538,750
+90,281
+20% +$85.8M 0.15% 125
2023
Q4
$394M Buy
448,469
+52,706
+13% +$43.4M 0.13% 144
2023
Q3
$326M Sell
395,763
-56,714
-13% -$44.6M 0.11% 164
2023
Q2
$325M Buy
452,477
+24,581
+6% +$19M 0.11% 153
2023
Q1
$352M Buy
427,896
+7,597
+2% +$5.73M 0.13% 149
2022
Q4
$303M Buy
420,299
+36,352
+9% +$26.8M 0.12% 168
2022
Q3
$264M Sell
383,947
-5,807
-1% -$3.65M 0.11% 180
2022
Q2
$230M Sell
389,754
-2,280
-0.6% -$1.48M 0.09% 212
2022
Q1
$272M Buy
392,034
+8,791
+2% +$5.56M 0.09% 212
2021
Q4
$242M Sell
383,243
-2,830
-0.7% -$1.74M 0.07% 238
2021
Q3
$234M Buy
386,073
+39,278
+11% +$24.4M 0.07% 244
2021
Q2
$194M Sell
346,795
-133,453
-28% -$67.6M 0.06% 305
2021
Q1
$227M Sell
480,248
-353,067
-42% -$172M 0.07% 248
2020
Q4
$403M Sell
833,315
-792,931
-49% -$428M 0.14% 141
2020
Q3
$910M Sell
1,626,246
-80,543
-5% -$48.8M 0.35% 59
2020
Q2
$1.06B Buy
1,706,789
+492,173
+41% +$279M 0.43% 45
2020
Q1
$593M Buy
1,214,616
+428,361
+54% +$177M 0.29% 76
2019
Q4
$295M Buy
786,255
+539,224
+218% +$181M 0.11% 177
2019
Q3
$68.5M Sell
247,031
-105,784
-30% -$31.3M 0.03% 519
2019
Q2
$110M Buy
352,815
+308,740
+700% +$103M 0.04% 396
2019
Q1
$18.1M Buy
44,075
+22,244
+102% +$9.16M 0.1% 319
2018
Q4
$8.15M Buy
21,831
+40
+0.2% +$14.6K 0.05% 422
2018
Q3
$8.8M Buy
21,791
+2,197
+11% +$836K 0.05% 455
2018
Q2
$6.76M Sell
19,594
-167
-0.8% -$52.2K 0.04% 451
2018
Q1
$6.8M Sell
19,761
-21,650
-52% -$7.53M 0.04% 438
2017
Q4
$15.6M Sell
41,411
-2,825
-6% -$1.14M 0.1% 304
2017
Q3
$19.8M Buy
44,236
+22,128
+100% +$10.5M 0.13% 247
2017
Q2
$10.9M Sell
22,108
-2,168
-9% -$949K 0.07% 390
2017
Q1
$9.41M Buy
24,276
+4,389
+22% +$1.63M 0.06% 431
2016
Q4
$7.3M Sell
19,887
-327
-2% -$124K 0.04% 538
2016
Q3
$8.13M Buy
20,214
+89
+0.4% +$35.7K 0.05% 437
2016
Q2
$7.03M Sell
20,125
-386
-2% -$149K 0.04% 436
2016
Q1
$7.39M Sell
20,511
-10,166
-33% -$4.19M 0.04% 398
2015
Q4
$16.7M Buy
30,677
+170
+0.6% +$92.1K 0.09% 245
2015
Q3
$14.2M Buy
30,507
+19
+0.1% +$10.2K 0.08% 276
2015
Q2
$15.6M Sell
30,488
-3,882
-11% -$1.89M 0.08% 291
2015
Q1
$15.5M Buy
34,370
+5,109
+17% +$2.17M 0.09% 309
2014
Q4
$12M Sell
29,261
-6,334
-18% -$2.49M 0.07% 352
2014
Q3
$12.8M Sell
35,595
-1,465
-4% -$491K 0.08% 331
2014
Q2
$10.5M Sell
37,060
-13,032
-26% -$3.86M 0.06% 360
2014
Q1
$15M Sell
50,092
-18,140
-27% -$5.59M 0.09% 281
2013
Q4
$18.8M Sell
68,232
-6,707
-9% -$1.93M 0.12% 244
2013
Q3
$23.4M Sell
74,939
-20,003
-21% -$5.26M 0.15% 188
2013
Q2
$21.4M Buy
+94,942
New +$22.1M 0.14% 198

Other funds holding REGN

Nuveen's REGN Position: Q2 2026 in Review

Nuveen reduced its Regeneron Pharmaceuticals (REGN) stake by 2.2% in Q2 2026, selling an estimated $30.7M and leaving 2,019,974 shares worth $1.26B. The position accounts for 0.3% of the portfolio, ranked #61.

Nuveen first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.6B in Q1 2026. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Nuveen held 2,019,974 shares of Regeneron Pharmaceuticals worth $1.26B as of Q2 2026.
  • Nuveen sold 45,090 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $30.7M.
  • Regeneron Pharmaceuticals made up 0.3% of Nuveen's portfolio in Q2 2026, its #61 holding.
  • Nuveen first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Nuveen's Regeneron Pharmaceuticals position peaked at $1.6B in Q1 2026.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.